BGJ398 is an orally available selective inhibitor of FGFR1, FGFR2, and FGFR3 that has been shown to potently inhibit tumor cell proliferation and tumor growth in various cancer models harboring genetic alterations in FGFR1/2/3. The gene discussed is FGFR2; the disease is neoplasm.